ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement

Université de Montréal gains access to ERS Genomics’ CRISPR/Cas9 patents, launching platforms for genome-wide screening and fostering research collaborations.

Pharmalittle: Bluebird’s sickle-cell screwups may prompt a sale; drugmakers raised prices on widely used meds without new clinical evidence

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because the usual routine of online meetings

December 11, 2023

J&J touts success of Vyvgart competitor in two autoimmune disease trials, including key myasthenia gravis study

Johnson & Johnson’s experimental antibody nipocalimab reduced the severity of symptoms related to two autoimmune conditions — first in a pivotal study for generalized myasthenia

February 6, 2024

OSE Immunotherapeutics’ Tedopi gets US patent for cancer

The latest patent will boost the Tedopi vaccine’s value proposition and offers protection in the region until 2037. Credit: Mufid Majnun on Unsplash. The United

July 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.